Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia

M. De Michele (), M. Iacobucci, A. Chistolini, E. Nicolini, F. Pulcinelli, B. Cerbelli, E. Merenda, O. G. Schiavo, E. Sbardella, I. Berto, L. Petraglia, N. Caracciolo, M. Chiara, S. Truglia and D. Toni
Additional contact information
M. De Michele: Sapienza University of Rome
M. Iacobucci: Sapienza University of Rome
A. Chistolini: Sapienza University of Rome
E. Nicolini: Sapienza University of Rome
F. Pulcinelli: Sapienza University of Rome
B. Cerbelli: Sapienza University of Rome
E. Merenda: Sapienza University of Rome
O. G. Schiavo: Sapienza University of Rome
E. Sbardella: Sapienza University of Rome
I. Berto: Sapienza University of Rome
L. Petraglia: Sapienza University of Rome
N. Caracciolo: Sapienza University of Rome
M. Chiara: Sapienza University of Rome
S. Truglia: Sapienza University of Rome
D. Toni: Sapienza University of Rome

Nature Communications, 2021, vol. 12, issue 1, 1-7

Abstract: Abstract Vaccine-induced thrombotic thrombocytopenia with cerebral venous thrombosis is a syndrome recently described in young adults within two weeks from the first dose of the ChAdOx1 nCoV-19 vaccine. Here we report two cases of malignant middle cerebral artery (MCA) infarct and thrombocytopenia 9-10 days following ChAdOx1 nCoV-19 vaccination. The two cases arrived in our facility around the same time but from different geographical areas, potentially excluding epidemiological links; meanwhile, no abnormality was found in the respective vaccine batches. Patient 1 was a 57-year-old woman who underwent decompressive craniectomy despite two prior, successful mechanical thrombectomies. Patient 2 was a 55-year-old woman who developed a fatal bilateral malignant MCA infarct. Both patients manifested pulmonary and portal vein thrombosis and high level of antibodies to platelet factor 4-polyanion complexes. None of the patients had ever received heparin in the past before stroke onset. Our observations of rare arterial thrombosis may contribute to assessment of possible adverse effects associated with COVID-19 vaccination.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25010-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25010-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25010-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().